doxorubicin hydrochloride has been researched along with Leukemia L 1210 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cory, M; Henry, DW; Lee, WW; Tong, GL | 1 |
| Adams, N; Blake, C; Broadhurst, MJ; Bushnell, DJ; Hartmann, HR; Hassall, CH; Keech, E; Stratton, AR; Thomas, GJ | 1 |
| Acton, EM; Mosher, CW; Tong, GL; Wolgemuth, RL | 1 |
| Kim, JK; Sohn, YS; Song, R; Toti, US | 1 |
4 other study(ies) available for doxorubicin hydrochloride and Leukemia L 1210
| Article | Year |
|---|---|
Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
Topics: Animals; Cells, Cultured; Daunorubicin; DNA, Neoplasm; Electrocardiography; Heart; Kinetics; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Mice; Rats; RNA, Neoplasm; Structure-Activity Relationship | 1978 |
Synthesis and antitumor activity of 9-[(carbamoyloxy)alkyl]anthracyclines: a novel class of anthracycline derivatives.
Topics: Animals; Antibiotics, Antineoplastic; Carbamates; Chemical Phenomena; Chemistry; Female; Leukemia L1210; Mice; Stereoisomerism; Structure-Activity Relationship | 1990 |
Intensely potent morpholinyl anthracyclines.
Topics: Animals; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation, Preclinical; Indicators and Reagents; Leukemia L1210; Leukemia P388; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Structure-Activity Relationship | 1984 |
A macromolecular prodrug of doxorubicin conjugated to a biodegradable cyclotriphosphazene bearing a tetrapeptide.
Topics: Animals; Antibiotics, Antineoplastic; Biodegradation, Environmental; Cell Line, Tumor; Doxorubicin; Inhibitory Concentration 50; Leukemia L1210; Magnetic Resonance Spectroscopy; Molecular Weight; Nitriles; Oligopeptides; Phosphorus Compounds; Polyethylene Glycols; Prodrugs; Stereoisomerism | 2005 |